Literature DB >> 21898141

IL-9 contributes to immunosuppression mediated by regulatory T cells and mast cells in B-cell non-hodgkin's lymphoma.

Li-Li Feng1, Jun-Ming Gao, Pei-Pei Li, Xin Wang.   

Abstract

It has been known that regulatory T (Treg) cells and mast cells (MCs) are involved in tumor immunity regulation, but the exact roles and mechanisms of Treg cells and MCs in B-cell non-Hodgkin's lymphoma (NHL) are incompletely defined. In the present study, we found that the number of Foxp3(+) Treg cells and CD117(+) MCs increased in B-cell NHL patients. Concomitantly, a high level of interleukin (IL)-9 was observed in the sera from B-cell NHL patients. Neutralizing IL-9 significantly inhibited tumor growth in the lymphoma model of murine, and this process was associated with down-regulation of Treg cells and MCs. Furthermore, IL-9 was also demonstrated to induce expression of MC-related genes and proliferation of MCs from the bone marrow stem cells. Collectively, our results indicate that Treg cell and MCs are involved in immunosuppression in B-cell NHL, and IL-9 is a key mediator of Treg cells and MCs in that process. These findings provide novel insight for the pathogenesis and possible therapeutic strategy of B-cell NHL.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21898141     DOI: 10.1007/s10875-011-9584-9

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  40 in total

Review 1.  Molecular pathogenesis of follicular lymphoma: a cross talk of genetic and immunologic factors.

Authors:  Daphne de Jong
Journal:  J Clin Oncol       Date:  2005-09-10       Impact factor: 44.544

2.  CD4+FOXP3+ regulatory T cell depletion by low-dose cyclophosphamide prevents recurrence in patients with large condylomata acuminata after laser therapy.

Authors:  Yuchun Cao; Jie Zhao; Zhuoshun Yang; Zaisheng Cai; Biao Zhang; Yu Zhou; Guan-Xin Shen; Xingping Chen; Shenqiu Li; Bo Huang
Journal:  Clin Immunol       Date:  2010-03-24       Impact factor: 3.969

3.  Prognostic influence of tumor-infiltrating mast cells in patients with follicular lymphoma treated with rituximab and CHOP.

Authors:  Minna Taskinen; Marja-Liisa Karjalainen-Lindsberg; Sirpa Leppä
Journal:  Blood       Date:  2008-02-28       Impact factor: 22.113

4.  Cd4+ T-cell immune response to large B-cell non-Hodgkin's lymphoma predicts patient outcome.

Authors:  S M Ansell; M Stenson; T M Habermann; D F Jelinek; T E Witzig
Journal:  J Clin Oncol       Date:  2001-02-01       Impact factor: 44.544

Review 5.  Treatment of mantle cell lymphoma: targeting the microenvironment.

Authors:  Johannes Drach; Sonja Seidl; Hannes Kaufmann
Journal:  Expert Rev Anticancer Ther       Date:  2005-06       Impact factor: 4.512

6.  Transient regulatory T-cells: a state attained by all activated human T-cells.

Authors:  Vinodh Pillai; Sterling B Ortega; C K Wang; Nitin J Karandikar
Journal:  Clin Immunol       Date:  2006-12-19       Impact factor: 3.969

7.  Mast cells are essential intermediaries in regulatory T-cell tolerance.

Authors:  Li-Fan Lu; Evan F Lind; David C Gondek; Kathy A Bennett; Michael W Gleeson; Karina Pino-Lagos; Zachary A Scott; Anthony J Coyle; Jennifer L Reed; Jacques Van Snick; Terry B Strom; Xin Xiao Zheng; Randolph J Noelle
Journal:  Nature       Date:  2006-08-20       Impact factor: 49.962

8.  IL-9-deficient mice establish fundamental roles for IL-9 in pulmonary mastocytosis and goblet cell hyperplasia but not T cell development.

Authors:  J M Townsend; G P Fallon; J D Matthews; P Smith; E H Jolin; N A McKenzie
Journal:  Immunity       Date:  2000-10       Impact factor: 31.745

9.  Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine.

Authors:  Marc Beyer; Matthias Kochanek; Kamruz Darabi; Alexey Popov; Markus Jensen; Elmar Endl; Percy A Knolle; Roman K Thomas; Michael von Bergwelt-Baildon; Svenja Debey; Michael Hallek; Joachim L Schultze
Journal:  Blood       Date:  2005-05-24       Impact factor: 22.113

10.  Vascular CD39/ENTPD1 directly promotes tumor cell growth by scavenging extracellular adenosine triphosphate.

Authors:  Lili Feng; Xiaofeng Sun; Eva Csizmadia; Lihui Han; Shu Bian; Takashi Murakami; Xin Wang; Simon C Robson; Yan Wu
Journal:  Neoplasia       Date:  2011-03       Impact factor: 5.715

View more
  26 in total

1.  Notch receptors and Smad3 signaling cooperate in the induction of interleukin-9-producing T cells.

Authors:  Wassim Elyaman; Ribal Bassil; Elizabeth M Bradshaw; William Orent; Youmna Lahoud; Bing Zhu; Freddy Radtke; Hideo Yagita; Samia J Khoury
Journal:  Immunity       Date:  2012-04-12       Impact factor: 31.745

2.  FoxP3(+) T regulatory cells in oral lichen planus and its correlation with the distinct clinical appearance of the lesions.

Authors:  Joabe S Pereira; Bárbara V Monteiro; Cassiano F Nonaka; Éricka J Silveira; Márcia C Miguel
Journal:  Int J Exp Pathol       Date:  2012-08       Impact factor: 1.925

Review 3.  Th9 cells in the pathogenesis of EAE and multiple sclerosis.

Authors:  Wassim Elyaman; Samia J Khoury
Journal:  Semin Immunopathol       Date:  2016-11-14       Impact factor: 9.623

Review 4.  The dichotomous function of interleukin-9 in cancer diseases.

Authors:  K Gerlach; B Weigmann
Journal:  J Mol Med (Berl)       Date:  2019-08-08       Impact factor: 4.599

5.  Comparative randomized trial evaluating the effect of proton pump inhibitor versus histamine 2 receptor antagonist as an adjuvant therapy in diffuse large B-cell lymphoma.

Authors:  Sahar K Hegazy; Sahar M El-Haggar; Suzan A Alhassanin; Eman I El-Berri
Journal:  Med Oncol       Date:  2021-01-04       Impact factor: 3.064

6.  Role of high expression of IL-9 in prognosis of CLL.

Authors:  Na Chen; Xiao Lv; Peipei Li; Kang Lu; Xin Wang
Journal:  Int J Clin Exp Pathol       Date:  2014-01-15

7.  Overexpression of IL-9 induced by STAT6 activation promotes the pathogenesis of chronic lymphocytic leukemia.

Authors:  Na Chen; Kang Lu; Peipei Li; Xiao Lv; Xin Wang
Journal:  Int J Clin Exp Pathol       Date:  2014-04-15

8.  Evaluation of Interleukin-9 Expression as a Potential Therapeutic Target in Chronic Lymphocytic Leukemia in a Cohort of Egyptian Patients.

Authors:  Hadeer A Abbassy; Reham A Aboelwafa; Omar M Ghallab
Journal:  Indian J Hematol Blood Transfus       Date:  2017-03-17       Impact factor: 0.900

9.  Overexpression of IL-9 receptor in diffuse large B-cell lymphoma.

Authors:  Xiao Lv; Lili Feng; Xiaosheng Fang; Yujie Jiang; Xin Wang
Journal:  Int J Clin Exp Pathol       Date:  2013-04-15

Review 10.  IL-9-producing T cells: potential players in allergy and cancer.

Authors:  Pornpimon Angkasekwinai; Chen Dong
Journal:  Nat Rev Immunol       Date:  2020-08-12       Impact factor: 53.106

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.